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Aims T-cadherin (T-cad) is a glycosylphosphatidylinositol-anchored cadherin family member. Experimental, clinical, and
genomic studies suggest a role for T-cad in vascular disorders such as atherosclerosis and hypertension, which are
associated with endothelial dysfunction and insulin resistance (InsRes). In endothelial cells (EC), T-cad and insulin ac-
tivate similar signalling pathways [e.g. PI3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)] and processes
(e.g. angiogenesis). We hypothesize that T-cad is a regulatory component of insulin signalling in EC and therefore a
determinant of the development of endothelial InsRes.
Methods
and results
We investigated T-cad-dependent effects on insulin sensitivity using human EC stably transduced with respect to
T-cad overexpression or T-cad silencing. Responsiveness to insulin was examined at the level of effectors of the
insulin signalling cascade, EC nitric oxide synthase (eNOS) activation, and angiogenic behaviour. Overexpression
and ligation of T-cad on EC attenuates insulin-dependent activation of the PI3K/Akt/mTOR signalling axis, eNOS,
EC migration, and angiogenesis. Conversely, T-cad silencing enhances these actions of insulin. Attenuation of EC re-
sponsiveness to insulin results from T-cad-mediated chronic activation of the Akt/mTOR-dependent negative feed-
back loop of the insulin cascade and enhanced degradation of the insulin receptor (IR) substrate. Co-
immunoprecipitation experiments revealed an association between T-cad and IR. Filipin abrogated inhibitory
effects of T-cad on insulin signalling, demonstrating localization of T-cad-insulin cross-talk to lipid raft plasma mem-
brane domains. Hyperinsulinaemia up-regulates T-cad mRNA and protein levels in EC.
Conclusion T-cad expression modulates signalling and functional responses of EC to insulin. We have identified a novel signalling
mechanism regulating insulin function in the endothelium and attribute a role for T-cad up-regulation in the patho-
genesis of endothelial InsRes.
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1. Introduction
Insulin resistance (InsRes) is typically defined as a decreased sensitiv-
ity/responsiveness to the metabolic actions of insulin that promote
glucose disposal in traditional target tissues (muscle, liver, and
adipose tissue) and is a hallmark of metabolic disorders including
type 2 diabetes and obesity. Recognition of the pathophysiological
importance of InsRes in non-traditional target tissues such as the
endothelium is more recent. Associated micro- and macrovascular
complications of metabolic disorders (e.g. retinopathy, nephropathy,
hypertension, atherosclerosis, coronary artery disease) are preceded
by a state of endothelial dysfunction (ED) which is characterized by
impaired nitric oxide (NO) bioavailability and vasorelaxation.
Diverse molecular and cellular reciprocal relationships between
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InsRes and ED in metabolic and vascular tissues are considered to
govern the frequent association between metabolic and cardiovascu-
lar disorders.1–5
Because endothelial cells (EC) do not possess the insulin-
stimulated glucose carrier GLUT4, insulin stimulation of the
cognate insulin receptor (IR) in EC has physiological consequences
that do not directly involve glucose intake. Insulin induces pleiotrop-
ic responses in the endothelium. It promotes vasorelaxation and ca-
pillary recruitment in peripheral tissues5 and is also a potent
pro-angiogenic molecule regulating neovascularization, EC migration,
and wound healing.6 These functions are mediated by a signalling
cascade involving IR substrate-1 (IRS-1), PI3-kinase (PI3K), Akt,
endothelial NO synthase (eNOS), and NO generation. Additionally,
insulin has vasoconstrictor and growth promoting functions that are
mediated through a signal cascade involving Ras, Raf, MAPK/extracel-
lular signal-related kinases and endothelin-1 synthesis and secretion.
Pathological outcomes of endothelial InsRes are complex and
include ED, impaired vasodilation, microvessel disease, enhanced
vascular inflammation, atherosclerosis, and hypertension.3 How
insulin signalling in the endothelium becomes impaired remains
unclear.
A striking feature of InsRes is that insulin activation of PI3K/Akt
signalling branch is selectively impaired.5,7 However, also chronic ac-
tivation of Akt signalling by hyperinsulinaemia or other factors may
contribute to the development of InsRes. Chronic insulin exposure
results in serine phosphorylation and degradation of IRS-1 and
IRS-2 with consequential down-regulation of insulin signalling in
the muscle, liver, and adipocytes.8,9 Insulin-induced glucose disposal
in these systems may be rescued by inhibition of mammalian target
of rapamycin (mTOR),8,9 while mTOR activation acutely inhibits
insulin-dependent Akt phosphorylation and glucose transport in
human adipocytes.10 In the heart, chronic Akt activation increases
basal glucose uptake but inhibits responses to insulin.11 Thus, hyper-
activation of the Akt/mTOR-dependent negative feedback pathway
of insulin signalling can render a state of insulin insensitivity/
resistance.
T-cadherin (T-cad), an atypical glycosylphosphatidylinositol
(GPI)-anchored member of the cadherin superfamily, is gaining rec-
ognition as a regulator of EC function.12 T-cad expression is
increased in vivo in human atherosclerotic lesions13 and experimental
restenosis,14 and in vitro on proliferating EC and smooth muscle
cells15 and on EC during oxidative and endoplasmic reticulum
stress.16,17 Overexpression and ligation of T-cad activate the PI3K/
Akt/mTOR signalling pathway and promote proliferation and angio-
genesis.16,18 Elevation of T-cad in human plasma correlates with clin-
ical progression of atherosclerosis and ED.19 Notably, in EC, T-cad
and insulin stimulate common signalling pathways (PI3K/Akt/
mTOR) and control similar (patho)physiological processes (angio-
genesis and ED). Additionally, T-cad acts as a heterophilic receptor
for adiponectin, an adipokine that regulates glucose and fatty acid
metabolism and mimics some effects of insulin.20 T-cad plays a crit-
ical role in binding of adiponectin to the vascular wall and mediates
its cardioprotective functions.21–23 These data prompted us to
hypothesize a cross-talk between insulin and T-cad signalling. We
demonstrate that T-cad overexpression in EC attenuates
insulin-induced activation of Akt pathway with concomitantly
reduced insulin-stimulated eNOS activation, migration, and angiogen-
esis, suggesting a role for T-cad in the pathogenesis of endothelial
InsRes and ED.
2. Methods
2.1 Cells and lentivector transduction
The investigation conforms with the principles outlined in the Declaration
of Helsinki for the use of human tissues. Human microvascular EC line
HMEC-124 was stably transduced with respect to T-cad overexpression
or T-cad-silencing (siTcad) and respective empty vector- (E) or non-target
shRNA (siC) controls using lentiviral vectors.25 Full-length human
c-myc-tagged T-cad was excised from adenovector26 and cloned into
pLVX-puro lentivector for stable transduction of HMEC-1. Transient
overexpression of T-cad in primary EC cultures from the human umbilical
vein (HUVEC; Promocell GmbH, Allschwil, Switzerland) and human aorta
(HAEC; Promocell) was achieved using adenovector-mediated transfec-
tion procedures.27 The application of viral vector-mediated transfection
was approved by the Swiss Federal Office for the Environment. Supple-
mentary material online provides details on vectors and culture condi-
tions, data on T-cad protein and transcript expression levels in the
transductants (see Supplementary material online, Figure S1), and proof
of surface localization of both endogenous and overexpressed T-cad
protein in HMEC-1 (see Supplementary material online, Figure S2).
2.2 Isolation of microparticles from
cultured EC
Procedures for harvesting microparticles (MP) from tumour necrosis
factor-a (TNFa)-stimulated E and Tcad transductants (respectively,
MP-E and MP-Tcad) and the preparation of controls to exclude any
trace of foetal calf serum (FCS) or cytokine have been described
before19 and are detailed in Supplementary material online. Briefly, the
medium was collected after culture in the presence of TNFa (50 ng/mL,
48 h) and clarified from dead cells and cell fragments (centrifugation at
3000 g, 15 min, 48C). Thereafter, MP were pelleted by ultracentrifugation
(100 000 g, 1 h, 48C), washed twice in phosphate-buffered saline (PBS),
resuspended in PBS, and used for stimulation of target EC cultures.
2.3 Cell activation and immunoblotting
Subconfluent cultures were incubated in low serum-containing medium
[DMEM/0.1% bovine serum albumin (BSA)/0.5% FCS] for 3 h before
stimulation with insulin or MP. Whole-cell lysates were prepared and ana-
lysed by immunoblotting as described.16 Primary antibodies against follow-
ing proteins/epitopes were used: T-cad (R&D Systems Europe Ltd,
Abingdon, UK), Akt, phospho (p)-AktSer473, p-AktThr308, mTOR,
p- mTORSer2448, S6RP, p-S6RPSer240/244, p70S6K, p-p70S6KThr389, IRS-1,
p-IRS-1Ser636/639, p-eNOSSer1177, insulin receptor-b (IRb) (Cell Signaling,
New England Biolabs GMBH, Frankfurt, Germany), c-myc (Clontech/
Takara Bio Europe, Saint-Germain-en-Laye, France), GAPDH (Abcam,
Cambridge, UK), and p-Tyr clone 4G10 (Millipore AG, Zug, Switzerland).
Secondary horseradish peroxidase-conjugated anti-species IgG were from
Southern Biotechnology (BioReba AG, Reinach, Switzerland).
2.4 Immunoprecipitation
HMEC-1 transduced with native T-cad or c-myc-tagged T-cad were
serum-deprived (3 h) in Cloneticsw Endothelial Cell Growth Medium
(ECGM) containing 1% BSA/0.5% FCS, then stimulated with insulin. Immu-
noprecipitation (IP) was performed26 with two different lysis buffers:
Triton X-114 buffer [Tris–HCl 50 mM (pH 8.0), 100 mM NaCl, 5 mM
CaCl2, 0.2% SDS, 1% Triton X-114] or NP-40 buffer [150 mM NaCl,
1% NP-40, and 50 mM Tris–HCl, pH 8.0]. Buffers were supplemented
with Complete Mini protease inhibitor cocktail. Anti-c-myc or anti-IRb
subunit antibodies were used for IP, with subsequent detection of T-cad
and IRb by immunoblotting. IP for IRS-1 was performed using NP-40
buffer and anti-IRS-1 antibodies, with subsequent immunoblot analysis
for IRS-1 and p-Tyr. Total amount of IgG in the pellets served as an intern-
al loading control.
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2.5 Wound assay and time-lapse
videomicroscopy
Assay for migration by time-lapse videomicroscopy of wound healing was
performed as detailed before.24 Confluent cultures were scrape-wounded
and serum-deprived (3 h) in DMEM/1% FCS/0.1% BSA and then exposed
to insulin. Wound closure was filmed (48 h, 1 frame/h) under an Olympus
IX-81 inverted time-lapse videomicroscope (Olympus Optical Co.,
Geneva, Switzerland). Acquired images were processed and analysed
for distance of cell migration into the wound area using CellR software
(Soft Imaging System GmbH, Muenster, Germany). Experiments con-
tained two parallel wells for every experimental condition, and in each
well, three different fields of observation at the initial wound front
(time 0) were randomly selected.
2.6 Endothelial tube-formation assay
The EC spheroid assay in 3D fibrin gels was performed as detailed18
except that spheroids (500 cells/spheroid) were prepared using the
‘hanging drop’ method28 and gels were overlaid with ECGM supplemen-
ted with 2% FCS without or with inclusion of 100 nM insulin and signalling
inhibitors. After 24 h incubation, spheroids were stained with TRITC-
conjugated phalloidin and sprout outgrowth was analysed morphometric-
ally (CellR software).18
2.7 Real-time polymerase chain reaction
Subconfluent cultures were serum-deprived (3 h) in DMEM/0.5% FCS/
0.1% BSA before insulin stimulation. T-cad transcript expression was mea-
sured by real-time polymerase chain reaction.29 Primer details are given in
Supplementary material online.
2.8 Statistical analysis
Unless otherwise stated, experiments were performed on at least three
independent occasions and results are given as mean+ SD. Differences
were determined using one-way repeated-measures ANOVA with
Tukey’s multiple comparison using GraphPad Prism 5.0 software (Graph-
Pad Software, San Diego, CA, USA). A P-value of ,0.05 was considered
significant.
3. Results
3.1 T-cad attenuates activation
of Akt/mTOR pathway by insulin
PI3K/Akt/mTOR signalling pathway is one of the main targets of
both T-cad and insulin in EC (see pathway depiction in Figure 6).
To investigate whether T-cad modulates signalling responses to
insulin, we compared Tcad and siTcad HMEC-1 with respect to
baseline and insulin-stimulated phosphorylation of key signalling
effectors within the Akt/mTOR cascade. Under baseline serum-
containing or serum-deprivation culture conditions, levels of
p-AktSer473, p-mTORSer2448, p-p70S6KThr389, and p-S6RPSer240/244
were higher in Tcad (vs. E) and lower in siTcad (vs. siC); as
expected, phosphorylation levels of all effectors were reduced
under serum-deprivation conditions (Figure 1A). These data agree
with our previous findings in HUVEC.16 Insulin (100 nM) induced
a rapid phosphorylation of Akt on Ser473 which was attenuated in
Tcad and enhanced in siTcad cells (Figure 1B). Accordingly, T-cad
overexpression attenuated and silencing promoted insulin-induced
phosphorylation of mTOR, an immediate downstream target of
Akt (Figure 1C), and of S6RP (Figure 1D) and p70S6 kinase (see Sup-
plementary material online, Figure S3A) which are downstream
targets of mTOR. Insulin-induced phosphorylation of Akt on
Thr308 was attenuated in Tcad cells, but not significantly modulated
by T-cad silencing (see Supplementary material online, Figure S3B).
The differential insulin responsiveness between Tcad and siTcad at
the level of p-AktSer473 was evident also at lower insulin concentra-
tions (1 and 10 nM; see Supplementary material online, Figure S4).
Attenuating effects of T-cad overexpression on insulin-stimulated
phosphorylation of Akt on Ser473 were true too for primary
HUVEC and HAEC cultures [see Supplementary material online,
Figures S4 (dose) and S5 (kinetics)].
3.2 T-cad expression modulates
phosphorylation and total protein
levels of IRS-1
A crucial initiating event in the insulin-dependent signalling cascade
is IR-induced phosphorylation of IRS-1 on Tyr1101 which recruits
the regulatory p85 subunit of PI3K, enabling downstream activation
of the Akt signalling axis.30 Attenuation of insulin signalling is
achieved by a negative feedback loop involving Akt-dependent
stimulation of mTOR complex with Raptor (mTORC1) and the ac-
tivation of S6K1 kinase which phosphorylates IRS-1 on Ser636/639,
causing IRS-1 dissociation from p85, inactivation, and degradation.31
To determine whether T-cad modulates IRS-1 expression and/or
activity, we analysed total and p-IRS-1 levels in transduced
HMEC-1. Levels of tyrosine phosphorylated IRS-1, analysed by IP
of total IRS-1 protein from insulin-stimulated cells followed by im-
munoblotting with anti-p-Tyr antibodies, were reduced in Tcad but
increased in siTcad relative to total IRS-1 (Figure 2A). Phosphoryl-
ation of IRS-1Ser636/639 was measured by direct immunoblotting of
lysates from untreated and insulin-treated cells and found to be ele-
vated in Tcad and decreased in siTcad, respectively (Figure 2B, upper
histogram). Importantly, both methods also revealed a reduction in
levels of total IRS-1 protein in Tcad and an increase in siTcad cells
under basal and insulin-stimulated conditions (Figure 2B, lower
histogram).
3.3 Tcad causes PI3K- and
mTOR-dependent degradation
of IRS-1 protein
To investigate whether T-cad modulates the IRS-1 protein level by
affecting its stability, we analysed kinetics of IRS-1 degradation in
transduced HMEC-1 cultured under normal conditions after treat-
ment with cycloheximide, which prevents protein synthesis de novo.
In the presence of cycloheximide, the decline in IRS-1 expression oc-
curred more rapidly in Tcad but was unaffected in siTcad cells
(Figure 2C). Inclusion of PI3K inhibitor LY-294002 or mTOR inhibitor
rapamycin under normal culture conditions rescued IRS-1 levels in
Tcad cells (Figure 2D). Thus, IRS-1 degradation induced by T-cad over-
expression is dependent on PI3K and mTOR activation.
3.4 T-cad ligation activates insulin
signalling pathway
Our previous investigations have demonstrated that T-cad-dependent
responses (including Akt phosphorylation) may be triggered by either
T-cad up-regulation on the cell surface (presumably via enhanced
clustering, lateral cis-ligation and recruitment adapter molecules) or
trans-ligation (via homophilic binding to T-cad molecules on neigh-
bouring cells or endothelial-derived MP, with recombinant T-cad
protein or agonistic antibodies).16,19,27 Here, we investigated
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whether T-cad ligation affects insulin signalling. Exposure of parental
HMEC-1 to MP harvested from E or Tcad HMEC-1 transductants
caused tyrosine phosphorylation of IRS-1 (Figure 3A) as well as
rapid and reversible elevation of p-IRS-1Ser636/639 relative to total
IRS-1 expression (Figure 3B), and these responses were more prom-
inent for MP-Tcad. While levels of total IRS-1 in parental HMEC-1
remained unchanged during short-term (up to 30 min) exposure to
MP (Figure 3B), they were reduced following longer term (4 h) incuba-
tion with MP, this effect being more prominent in the case of MP-Tcad
(Figure 3C).
3.5 T-cad interacts with IR
In addition to the ability of T-cad to regulate insulin signalling pathway
by cross-talk with signalling networks downstream of IR, direct inter-
actions between IR and T-cad in the plasma membrane might repre-
sent an alternative mode of regulation. To explore the latter
possibility, we performed co-IP experiments. Two different lysis
buffers were used: standard NP-40 buffer and a raft-solubilizing
Triton X-114 buffer that has been successfully used for identification
of molecules specifically associating with GPI-anchored proteins.26
Using either of these extraction approaches and anti-IRb antibodies
for IP of lysates from Tcad cells, we found that T-cad co-precipitated
with IR (Figure 4A). Due to lack of commercially available anti-T-cad
antibodies suitable for IP, we performed reverse co-IP using
HMEC-1 expressing T-cad protein with c-myc tag and anti-c-myc anti-
body.26 This approach demonstrated co-precipitation of IR with
T-cad, confirming physical association of the two proteins in the
plasma membrane (Figure 4B).
3.6 T-cad effects on insulin signalling
depend on lipid raft localization
To assess the importance of plasma membrane lipid raft domains for a
cross-talk between T-cad and insulin signalling, we measured
insulin-induced Akt phosphorylation after pre-treating EC with
filipin, a cholesterol-binding compound that disrupts lipid rafts.
Filipin (3 mg/mL) inhibited insulin-dependent activation of AktSer473
phosphorylation in Tcad, E, and siC transductants but not in the
siTcad cells (Figure 4C). This suggests that the presence of T-cad
and its interaction with IR is needed for localization of IR to lipid
rafts, whereas siTcad may enable redistribution of IR away from this
compartment and thereby render the pathway insensitive to lipid
raft disruption.
Figure 1 T-cad modulates activation of Akt/mTOR pathway by insulin. (A) Immunoblots showing phosphorylation status of Akt/mTOR signalling
cascade components in HMEC-1 under normal culture conditions or following serum deprivation (whole-cell lysates loaded at 5 and 10 mg, respect-
ively). Insulin (100 nm)-stimulated transductants were analysed by immunoblotting for total and phosphorylated AktSer473 (B), mTOR (C ), and S6RP
(D). Changes in phosphorylated/total effector ratios in Tcad and siTcad are expressed relative to those in their respective E and siC 0 time controls.
*P at least ,0.05 for Tcad vs. E or siTcad vs. siC. Total effector levels did not differ between the transductants and remained constant regardless of
the experimental condition (i.e. serum-containing, serum-deprivation insulin stimulation).
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3.7 T-cad overexpression attenuates
and silencing promotes insulin-induced
phosphorylation of eNOS, cell migration,
and angiogenesis in vitro
Tyrosine phosphorylation of IRS-1 triggers PI3K-dependent activation
of Akt which in its turn directly phosphorylates eNOS on Ser1177
leading to NO production and vasorelaxation.32 Therefore, we ana-
lysed whether T-cad-dependent modulation of insulin signalling also
changes eNOS activity. Insulin-induced phosphorylation of eNOS
was decreased in Tcad and enhanced in siTcad cells (Figure 5A). Inter-
estingly, under basal conditions, siTcad exhibited a moderate but re-
producible down-regulation of p-eNOSSer1177 levels when compared
with siC, yielding a greatly augmented insulin response (calculated as
increase in p-eNOSSer1177/eNOS vs. siC 0 time).
Insulin-dependent stimulation of cell migration is an important com-
ponent of wound healing and angiogenesis. We studied the role for
T-cad in modulation of insulin effects on EC migration by measuring
wound closure rates using time-lapse videomicroscopy. As demon-
strated previously,27 T-cad overexpression per se increased and
T-cad silencing decreased migration of EC into the wound area
under basal non-stimulated conditions (basal data as obtained in this
study are not shown). However, insulin-dependent migration was
less in Tcad cells and more pronounced in siTcad cells (Figure 5B).
Stimulation of the PI3K/Akt pathway in EC by insulin results in ac-
tivation of angiogenesis. We measured the influence of T-cad expres-
sion on insulin-induced angiogenesis using the 3D-spheroid in vitro
assay. Insulin increased (vs. unstimulated) total sprout outgrowth
from E and siC spheroids (Figure 5C). Insulin-induced angiogenesis
was abrogated in Tcad spheroids and enhanced in siTcad spheroids
(Figure 5C). Inclusion of either rapamycin or LY-294002 normalized
effects of T-cad on insulin-induced sprout outgrowth (Figure 5D),
demonstrating involvement of PI3K and mTOR in T-cad-dependent
modulation of the proangiogenic actions of insulin.
3.8 Insulin up-regulates T-cad expression in
EC via reactive oxygen species-dependent
mechanism
To determine whether insulin might modulate T-cad expression, we
treated parental HMEC-1 with 100 nM insulin. Insulin induced a time-
dependent increase in T-cad protein and mRNA (see Supplementary
Figure 2 T-cad modulates phosphorylation and total protein levels of IRS-1. (A) Following insulin stimulation (100 nM, 15 min), IRS-1 was immu-
noprecipitated using anti-total IRS-1 antibody and Tyr phosphorylation determined by immunoblotting with anti-p-Tyr antibody. (B) Immunoblot ana-
lysis for p-IRS-1Ser636/639 and total IRS-1 after insulin (100 nM) stimulation. Ratios of total IRS-1/GAPDH or p-IRS-1Ser636/639/total IRS-1 in Tcad and
siTcad are expressed relative to those in their respective unstimulated E and siC controls. *P at least ,0.05 for Tcad vs. E or siTcad vs. siC. (C)
Immunoblot analysis for total IRS-1 following incubation with 5 mg/mL cycloheximide under normal culture conditions. IRS-1 is expressed relative
to levels (arbitrarily taken as 100%) in the absence of cycloheximide. *P at least ,0.05 for Tcad vs. E, siTcad, or siC. (D) E and Tcad were incubated
(6 h) without (Ctrl) or with rapamycin (Rapa, 10 nM) or LY-294002 (LY, 20 mM). IRS-1, p-AktSer473, and p-S6RPSer240/244 were measured (inhibited
phosphorylation of AktSer473 and S6RPSer240/244 validates the efficacy of LY-294002 and rapamycin, respectively). IRS-1 is expressed relative to the level
in E Ctrl. *P at least, 0.05 between treated and untreated Tcad.
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material online, Figure S6). Inclusion of reactive oxygen species (ROS)
scavenger N-acetylcysteine inhibited insulin-induced up-regulation of
T-cad transcription (see Supplementary material online, Figure S6).
4. Discussion
This study has identified a novel mechanism for the regulation of
insulin sensitivity in the endothelium. Levels of T-cad expression in
EC profoundly modulate insulin responsiveness as manifested by
altered insulin-induced stimulation of PI3K/Akt/mTOR signalling and
accordingly altered vasorelaxant, promigratory, and proangiogenic
actions of insulin. Up-regulation of T-cad promotes InsRes, while
down-regulation of T-cad favours insulin sensitivity.
The most obvious explanation for T-cad-associated promotion of
InsRes in EC is that T-cad overexpression causes chronic activation
of the PI3K/Akt pathway,16–18 resulting in IRS-1 degradation and con-
sequential EC insensitivity to insulin stimulation. To understand the
sequence of events leading to T-cad-dependent InsRes in EC, one
must distinguish between effects of T-cad on components of the
insulin cascade in either the absence (basal) or the presence of
insulin. Our previous investigations in EC demonstrated that T-cad
overexpression and ligation increase AktSer473 and GSK3b phosphor-
ylation and nuclear translocation of b-catenin in a PI3K/mTOR-
dependent manner to promote proliferation, survival, and angiogen-
esis.16–18 Here, and in accordance with the basal status of Akt/
mTOR signalling in Tcad (enhanced) and siTcad (decreased) cells
(Figure 1A), in the absence of insulin, Tcad exhibited faster degradation
rates and reduced levels of IRS-1, while siTcad displayed some stabil-
ization of IRS-1 protein (Figure 2). Consistent with IRS-1 being an es-
sential component of insulin signalling,30,31 Tcad (with pre-degraded
IRS-1) responded poorly to insulin, whereas siTcad (with constitutive-
ly higher IRS-1) exhibited increased responsiveness. This differential
was manifest with respect to PI3K/Akt/mTOR signalling (Figure 1),
IRS-1 phosphorylation on tyrosine and serine residues (Figure 2),
eNOS phosphorylation, migration, and sprouting (Figure 5).
How T-cad activates basal Akt signalling and the negative feedback
loop in the insulin signalling cascade is unclear. GPI-anchorage of
T-cad implies a requirement for transmembrane adaptors that interact
with T-cad on the outer plasma membrane surface and enable signal
transmission to cytoplasmic downstream targets. We previously
Figure 3 T-cad ligation affects insulin signalling. Parental HMEC-1 was stimulated or not (Ctrl) with MP collected from Tcad (MP-Tcad) or E (MP-E)
HMEC-1. (A) Tyr phosphorylation of IRS-1 after 15 min stimulation was determined by IRS-1 IP and immunoblotting with anti-p-Tyr antibody. (B)
p-IRS-1Ser636/639 and total IRS-1 were measured by immunoblot analysis of whole-cell lysates after up to 30 exposure to MP. Levels of total IRS-1
did not change. Ratios of p-IRS-1Ser636/639/total IRS-1 are expressed relative to that of Ctrl/0 time. *P at least ,0.05 for MP-Tcad vs. MP-E. (C) Whole-
cell lysates were probed for total IRS-1 levels by immunoblotting after 4 h stimulation.
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demonstrated lipid raft domain localization of T-cad in EC and smooth
muscle cells33 and identified several membrane partners, including
Grp78/BiP, integrin-linked kinase, and integrin b3.26,34 The first two
participate in T-cad-dependent activation of Akt.26,34 Thus, one ex-
planation for the ability of T-cad to impact insulin signalling is that
its adaptor recruitment activates signalling responses (e.g. Akt activa-
tion) that converge with the insulin-IR-dependent pathway at the level
of common intracellular targets. Another possibility is that T-cad
increases basal Akt activity via direct activation of IR. Like T-cad, IR
is present in plasma membrane lipid raft domains.33,35 Correlations
between lipid membrane composition, membrane viscosity, and IR
activity suggest some link between lipid raft localization of IR and
InsRes.35 Our IP experiments demonstrated that T-cad and IR co-
precipitate, and abrogation of inhibitory effects of T-cad on the
insulin cascade by filipin supports lipid raft localization of insulin-T-cad
cross-talk (Figure 4). Functional relevance of this interaction is sup-
ported through the use of EC-derived MP (which harbour T-cad)
to mimic surface homophilic ligation.19 EC-derived MP stimulate Akt
activation and angiogenic behaviour in target EC19 and, as shown
herein, also stimulate tyrosine and serine phosphorylation of IRS-1,
with amplification of these responses for Tcad cell-derived MP
(Figure 3). Both T-cad/IR co-precipitation and effects of T-cad
Figure 4 T-cad interacts with IR. (A) IR was immunoprecipitated (IP) from Tcad transductants using anti-IRb antibody or non-immune IgG (IP n/i).
Two different lysis buffers containing NP-40 or Triton X-114 were used. (B) T-cad was IP from HMEC-1 transduced with c-myc-tagged-T-cad protein
after incubation without or with insulin (100 nM, 15 min) using anti-c-myc antibody or n/i IgG. (A and B) The presence of IR and T-cad in immuno-
precipitates was checked by immunoblotting (WB). (C) Filipin-pre-treated (30 min, 3 mg/mL) cells were stimulated with insulin (100 nM, 15 min) and
immunoblotted for p-AktSer473. Changes in p-AktSer473 levels in E or Tcad and siC or siTcad are expressed relative to levels in E and siC controls,
respectively. *P at least ,0.05 between filipin-treated cells vs. the same non-treated cell type.
M. Philippova et al.504
harbouring MP on insulin-related signal pathway activity occur even in
the absence of insulin, suggesting that T-cad per se can utilize compo-
nents of the insulin signalling cascade to exert its effects on EC.
Insulin-like growth factor-1 receptor (IGF-1R) is structurally similar
to IR and can also bind insulin, albeit at ≈100 times lower affinity.36
Additionally, insulin can also bind with low affinity to hybrid receptors
composed of subunits from the different receptor types, although it
has been questioned whether signalling of insulin through hybrid
receptors is physiologically relevant.37 We have not yet addressed
whether T-cad effects on insulin signal pathway activity in EC also
involve interaction with IGF-1R. However, T-cad expression in EC
clearly affects insulin-induced Akt pathway activation at doses relevant
for both IR (1–10 nM) and IGF-1R (100 nM).
This study also offers new insight on roles for T-cad during condi-
tions associated with EC activation/dysfunction. Previous publications
demonstrated beneficial prosurvival functions for T-cad in vascular
EC.16,17 Since basal T-cad-dependent Akt activation promotes cell
survival during oxidative and endoplasmic reticulum stress16,17 and
facilitates angiogenesis,18,27 T-cad-up-regulation on vascular cells in
atherosclerosis and restenosis was interpreted as a protective and re-
generative cell response to unfavourable proinflammatory and dam-
aging conditions. Positive effects of T-cad-up-regulation in the vessel
are also linked to actions of adiponectin, identified as a heterophilic
ligand for T-cad.23 Adiponectin mimics some effects of insulin and,
in EC, through adiponectin receptors AdipoR1/AdipoR2, stimulates
NO production and angiogenesis by promoting a cross-talk
between AMPK and Akt. Since T-cad expression is critical for adipo-
nectin interactions with the vessel and its cardioprotective effects
during ischaemic injury,21,22 one might expect T-cad up-regulation
to promote beneficial metabolic and protective influences of adipo-
nectin in the cardiovasculature. The role for T-cad per se in regulation
of vascular tone is unknown.
This study provides the first direct demonstration of an important
deleterious consequence of T-cad up-regulation in EC, namely pro-
gression of endothelial InsRes. Moreover, our data may offer a mech-
anistic link between elevation of T-cad in the vessel and blood and
progression of cardiovascular disease. T-cad up-regulation on acti-
vated EC at early disease stages is likely due to thioredoxin-mediated
modulation of T-cad gene expression29 and aims at overriding
damaging effects of oxidative stress caused by inflammatory
events within the vessel. Based on our current finding that unstimu-
lated T-cad-silenced cells exhibit slightly lower p-eNOS levels, it
cannot be excluded that T-cad, via Akt pathway signalling, might par-
ticipate in maintenance of basal eNOS activity/vasorelaxation. Yet,
Figure 5 T-cad regulates functional effects of insulin on eNOS activation, cell motility, and angiogenesis. (A) Insulin (100 nM)-stimulated transduc-
tants were analysed by immunoblotting for total and p-eNOS. Total eNOS levels were neither different between the transductants nor altered by
insulin. p-eNOSSer1177/eNOS ratios in Tcad or siTcad are expressed relative to levels in their respective 0 time E and siC controls. *P at least ,0.05
for Tcad vs. E or siTcad vs. siC. (B) Scrape-wounded monolayer cultures were stimulated with 100 nM insulin, and wound closure filmed for 48 h.
Insulin-stimulated migration for each transductant is expressed relative to their migration in the absence of insulin. *P at least ,0.05. (C) Morpho-
metric analysis of the total length of sprout outgrowth per spheroid (at least 20 for each experimental point) after 24 h incubation without
(control) or with inclusion of insulin (100 nM) in the medium overlay. *P at least ,0.05 for insulin-stimulated vs. non-stimulated cells; §P at least
,0.05 for Tcad vs. E or siTcad vs. siC. (D) Rapamycin (10 nM, Rapa) or LY-294002 (20 mM, LY) was included in the medium overlay 1 h before
and throughout the 24 h incubation. *P at least ,0.05 for insulin-stimulated vs. non-stimulated cells.
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sustained T-cad up-regulation would result in attenuation of insulin
signalling. Subsequent enhanced ligation of T-cad molecules on the
endothelium by circulating MP harbouring increased levels of
T-cad,19 although initially able to activate insulin signalling pathway
components, would eventually, upon chronic exposure, also cause
inactivation of this pathway. Importantly, as we demonstrate here
in vitro, an increase in T-cad protein and transcript expression in
EC might be caused not only by oxidative stress, but also by pro-
longed exposure of cells to insulin. Furthermore, transcriptional
up-regulation of T-cad in EC by insulin can be prevented by ROS
scavenger N-acetylcysteine, which is in accordance with the
reported role for NADPH oxidase-produced ROS in insulin signal-
ling38 and the presence of ROS-sensitive elements in T-cad pro-
moter.29 Therefore, in vivo, hyperinsulinaemia initiated as a
compensatory response to loss of insulin sensitivity might also
lead to T-cad up-regulation and T-cad-dependent inactivation of
insulin signalling, further promoting the vicious cycle of InsRes pro-
gression. Exacerbation of endothelial InsRes would in its turn result
in ED manifest as reduced insulin-dependent release of relaxing
factors (e.g. NO) and impaired endothelium-dependent vasodilation
which plays an important role in the pathophysiology of essential
hypertension.39 Our current view on a cross-talk between T-cad,
insulin, eNOS, and angiogenesis in EC and the putative pathophysio-
logical consequences for vessel function is schematically depicted
in Figure 6.
There is mounting interest in the role for T-cad in pathogenesis of
metabolic disorders. Recent genome-wide association studies suggest
that apart from mediating interactions of adiponectin with the vascular
wall, T-cad might also modulate plasma levels of adiponectin.40,41
Tyrberg et al.42 demonstrated that T-cad-KO mice display progressive
glucose intolerance, attributable to a necessary requirement of T-cad
for insulin secretion from pancreatic b-cells. We have identified
another aspect of T-cad involvement in regulation of insulin function,
namely, a direct ability of T-cad to modulate activity of the insulin sig-
nalling cascade in the endothelium. Clinical and experimental data
suggest a tight reciprocal relationship between ED and InsRes. ED is
a characteristic feature of diabetes and obesity and, together with
endothelial InsRes, has been suggested to precede the development
of metabolic InsRes. Disclosure of T-cad-dependent control of endo-
thelial insulin sensitivity as a novel signalling pathway at the cross-
roads of vascular and metabolic disorders advances our understanding
of the complicated network of cellular mechanisms responsible for
vascular InsRes and associated vascular dysfunction.
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Figure 6 Proposed model for a cross-talk between T-cad and insulin signalling in EC and its pathophysiological consequences. (A) Under normal
physiological conditions, there is a balance between the activation of the insulin (ins) signalling cascade flowing downstream from IR to Akt and
mediated by tyrosine phosphorylation of IRS-1, and the negative regulatory loop running from Akt to S6K1 and mediated by serine phosphorylation
of IRS-1. Functionally, it sustains appropriate angiogenic and vasorelaxant responses of the endothelium to insulin. (B) Increased expression and ligation
of T-cad on the cell surface caused by oxidative stress, inflammation, or prolonged exposure to insulin results in chronic stimulation of the Akt
cascade, which in its turn induces compensatory hyperactivation of the negative feedback loop, increased serine phosphorylation of IRS-1, its degrad-
ation, and shutdown of the signalling. This leads to loss of insulin sensitivity in EC, attenuation of insulin-dependent angiogenesis and vasorelaxation,
and the progression of ED. Solid lines, insulin-induced signalling; dashed lines, T-cad-dependent signalling.
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